EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY-NC-ND 4.0

Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer

Joshua S Cheruvathur, Gabriel Levin iD, Reitan Ribeiro, Florentin Racovitan, Joanne Power, Xing Zeng, John Sampalis, Lucy Gilbert

International Journal of Gynecology & Obstetrics · 2026

DOI: 10.1002/ijgo.70336 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Gynecology & Obstetrics, 2026. Verfasst von Joshua S Cheruvathur und 7 weiteren Autor:innen. Beteiligte Einrichtung: Women's Health Research Unit, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Cystadenocarcinoma, Serous, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To compare overall survival (OS) in patients with high‐grade serous ovarian cancer (HGSOC) treated with intraperitoneal (IP) chemotherapy versus intravenous (IV) chemotherapy.

Methods

A retrospective study of Stage III HGSOC with optimal primary cytoreduction during 2007–2019, followed by adjuvant IP or IV chemotherapy.

Results

Overall, 54 patients were included, 23 (43%) treated by IP and 31 (57%) by IV chemotherapy. Median progression‐free survival (PFS) in the IP group was 39 months (95% confidence interval [CI] 34–44 months) versus 23 months (95% CI 18–28 months) in the IV group ( P = 0.294). The IP chemotherapy had superior OS compared with IV chemotherapy, with median OS not reached, versus 76 months (95% CI 37–115 months) for the IV group ( P = 0.075, hazard ratio 0.45, 95% CI 0.18–1.10). At 72 months, OS was 82% for the IP group versus 53% in the IV group. In a sensitivity analysis for Stage IIIc patients only ( n = 39), the median OS was 130 months (95% CI 86–174 months) in the IP group, compared with 56 months (95% CI 35–76 months) for the IV group ( P = 0.152). Toxicity profiles were similar in both groups, with no Grade ≥3 toxicity.

Conclusion

Stage III HGSOC patients treated with IP chemotherapy had significantly longer OS.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsCystadenocarcinoma, SerousAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMiddle AgedAgedAdultNeoplasm StagingProgression-Free SurvivalCytoreduction Surgical ProceduresInfusions, ParenteralChemotherapy, AdjuvantAdministration, Intravenous

Stichwörter der Autor:innen

high‐grade serous ovarian cancerintraperitoneal chemotherapyintravenous chemotherapyprimary cytoreductive surgery

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • Women's Health Research Unit, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
  • Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, McGill University Health Centre, Montreal, Quebec, Canada.
  • Department of Surgery, Division of Surgical Research, McGill University, Montreal, Quebec, Canada.
  • JSS Medical Research, Montreal, Quebec, Canada.

ORCID-Profile: Gabriel Levin

Zitieren

APA

Cheruvathur, J. S., Levin, G., Ribeiro, R., Racovitan, F., Power, J., Zeng, X., Sampalis, J., & Gilbert, L. (2026). Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer. International Journal of Gynecology & Obstetrics. https://doi.org/10.1002/ijgo.70336

Vancouver

Cheruvathur JS, Levin G, Ribeiro R, Racovitan F, Power J, Zeng X, et al. Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer. International Journal of Gynecology & Obstetrics. 2026. doi:10.1002/ijgo.70336

BibTeX
@article{Cheruvathur2026,
  author = {Cheruvathur, Joshua S and Levin, Gabriel and Ribeiro, Reitan and Racovitan, Florentin and Power, Joanne and Zeng, Xing and Sampalis, John and Gilbert, Lucy},
  title = {Revisiting intraperitoneal chemotherapy for advanced high‐grade serous ovarian cancer},
  journal = {International Journal of Gynecology & Obstetrics},
  year = {2026},
  doi = {10.1002/ijgo.70336}
}
Kostenlos starten →